Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Response's flu test:

This article was originally published in Clinica

Executive Summary

Response Biomedical has received US 510(k) clearance of its influenza A and B diagnostic, Flu A+B test. The rapid, point-of-care test will run on the Vancouver, Canada-based firm's new RAMP analyser platform, the RAMP 200. It will be marketed and sold exclusively worldwide by 3M Health Care as the 3M Rapid Detection Flu A+B Test. Response filed the 510(k) application in June 2007 (see Clinica No 1260, p 22). 3M Health Care plans to launch the test before the 2008-09 flu season in certain markets, and added it would be the first product sold in the US as part of its medical diagnostics platform.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel